SEC Tracker
Get the app

Design Therapeutics DSGN

Design Therapeutics reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. R&D expenses: $16.9 million for Q3 2026
  2. Net loss: $20.3 million for Q3 2026
  3. Cash and securities: $208.6 million as of September 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Design Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Alector ALEC public float $115M, Jun 30, 2025
  2. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  3. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  4. Caribou Biosciences CRBU public float $113M, Jun 30, 2025
  5. Protara Therapeutics PRTO public float $112M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.